On September 26, 2024, in Shanghai —— The final of the 2024 "Maker China" Shanghai SME Innovation and Entrepreneurship Competition was held at the Zhangjiang Science Hall.

Recently, Professor Ma Fei, Chief Physician, Professor, Doctoral Tutor, and Distinguished Professor of the Yangtze River Scholars Program at the Cancer Hospital of the Chinese Academy of Medical Sciences, as the national Leading PI of the ADC drug ESG401 clinical trial developed by Escugen, will present the research results of ESG401 at the 2024 ESMO Annual Meeting.